Pfizer Wins Pediatric Hemophilia Nod; GSK Eyes Nuvalent

Pfizer ($PFE) received FDA approval to expand the HYMPAVZI label to include pediatric hemophilia A and B patients as young as six, with and without inhibitors. The approval marks the first subcutaneous non-factor therapy approved for hemophilia B patients ages 6 to 11. $PFE currently trades at $25.62 and pays a 6.7% dividend yield, though the stock is up only 6.37% year-to-date. Separately, GlaxoSmithKline announced a $10.6 billion buyout offer for Nuvalent, sending Nuvalent shares to an all-time high.

Eli Lilly ($LLY) received a price target increase from Jefferies to $1,350 from $1,330, maintaining a Buy rating following the release of full data from an unspecified study. Competition in the oral weight-loss drug market intensified as Novo Nordisk's Wegovy pill surpassed 3 million prescriptions, a milestone that shows strong early demand as the Danish drugmaker competes with $LLY in the oral GLP-1 space. Bristol Myers Squibb ($BMY) launched a lung cancer detection and care model in underserved Brazilian communities using mobile CT units and telemedicine.

Intuitive Surgical ($ISRG) closed at $426.61, rising 1.91% in a session where the broader market declined. The surgical robotics leader saw its fair value estimate reset from $611.82 to $565.25, reflecting a lower price target that blends optimism about long-term growth potential with caution around weaker medtech sentiment and a reset in sector valuations. Abbott Laboratories ($ABT) fell 26% and is described as fairly valued following its first-quarter results and the impact of its Exact Sciences deal. DexCom ($DXCM) outpaced the market over the past month due to positive news and upbeat results, though specific performance metrics were not disclosed.

UnitedHealth Group ($UNH) surged to a 52-week high as Mizuho raised its price target to $460 from $440, reiterating an Outperform rating on the shares. Mizuho stated it believes the managed care sector is moving into a more favorable phase, though the firm did not provide specific catalysts for the improved outlook. Healthcare stocks rose broadly late in the session, with the NYSE Healthcare Index climbing 1.6%. Separately, analysts highlighted CVS Health as presenting a compelling turnaround opportunity, citing improved retail pharmacy market share and other positive growth signs.

Cytospire Therapeutics appointed Dr. Samit Hirawat as Non-Executive Director as the UK-based biotech prepares CYT X300, its lead pan-gamma delta T cell engager, for clinical trials. Dr. Hirawat is the former Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb ($BMY) and former EVP and Head of Oncology Development at Novartis. Gilead Sciences ($GILD) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, with Chairman and CEO Daniel O'Day participating. Separately, Lakefront Biotherapeutics announced the launch of a €50 million share repurchase program under which the company may repurchase ordinary shares through December 31, 2026.